| Metastatic non-small cell lung cancer
Tepmetko vs Vizimpro
Side-by-side clinical, coverage, and cost comparison for metastatic non-small cell lung cancer.Deep comparison between: Tepmetko vs Vizimpro with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVizimpro has a higher rate of injection site reactions vs Tepmetko based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Vizimpro but not Tepmetko, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Tepmetko
Vizimpro
At A Glance
Oral
Daily
MET kinase inhibitor
Oral
Daily
EGFR inhibitor
Indications
- Metastatic non-small cell lung cancer
- Metastatic non-small cell lung cancer
Dosing
Metastatic non-small cell lung cancer 450 mg orally once daily with food until disease progression or unacceptable toxicity; dose reduction to 225 mg once daily for adverse reactions, with permanent discontinuation if 225 mg is not tolerated.
Metastatic non-small cell lung cancer 45 mg orally once daily until disease progression or unacceptable toxicity; may be taken with or without food.
Contraindications
—
—
Adverse Reactions
Most common (>=20%) Edema, nausea, fatigue, musculoskeletal pain, diarrhea, dyspnea, decreased appetite, rash
Serious Pleural effusion, pneumonia, edema, general health deterioration, dyspnea, musculoskeletal pain, pulmonary embolism
Most common (>20%) Diarrhea, rash, paronychia, stomatitis, decreased appetite, dry skin, decreased weight, alopecia, cough, pruritus
Serious Diarrhea, interstitial lung disease
Pharmacology
Tepotinib is a kinase inhibitor that targets MET, including variants with exon 14 skipping alterations, inhibiting HGF-dependent and -independent MET phosphorylation and MET-dependent downstream signaling pathways.
Dacomitinib is an irreversible inhibitor of the kinase activity of the human EGFR family (EGFR/HER1, HER2, and HER4) and certain EGFR activating mutations (exon 19 deletion or exon 21 L858R substitution mutation), demonstrating dose-dependent inhibition of EGFR and HER2 autophosphorylation and tumor growth in preclinical models.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Tepmetko
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (12/12)
Vizimpro
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Tepmetko
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (0/8) · Qty limit (2/8)
Vizimpro
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Tepmetko
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Vizimpro
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Non-Small Cell Lung Cancer (NSCLC)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Non-Small Cell Lung Cancer (NSCLC)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
TepmetkoView full Tepmetko profile
VizimproView full Vizimpro profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.